A new combination of chemotherapy drugs could become the main therapy for pancreatic cancer, say UK researchers. The data presented at the world’s biggest cancer conference, the American Society of Clinical Oncology’s annual conference, showed that long-term survival of the disease could be increased from 16% to 29% with the new drugs. The findings have been described as a major win and as offering new hope to patients.
Pancreatic cancer is one of the most deadly cancers, with patients often given just months to live after diagnosis.